about
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotypeB Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsFollicular Helper CD4+ T Cells in Human Neuroautoimmune Diseases and Their Animal ModelsProfile of atacicept and its potential in the treatment of systemic lupus erythematosusRole of regulatory b cells in neuroimmunologic disordersElevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remissionAxon growth inhibition by RhoA/ROCK in the central nervous system.Circulating CCR7+ICOS+ Memory T Follicular Helper Cells in Patients with Multiple Sclerosis.Change of Th17 Lymphocytes and Treg/Th17 in Typical and Atypical Optic NeuritisEfficacy and safety of rituximab in neuromyelitis optica: Review of evidence.A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients.Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitroCD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics.Increased Circulating T Follicular Helper Cells Are Inhibited by Rituximab in Neuromyelitis Optica Spectrum Disorder.IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis.Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition.Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Death-Ligand 1.Anti-CD20 monoclonal antibodies in multiple sclerosis.Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases.Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controllSynthesis of a Bifunctional Peptide Inhibitor-IgG1 Fc Fusion That Suppresses Experimental Autoimmune Encephalomyelitis.Circulating regulatory B cell subsets in patients with neuromyelitis optica spectrum disorders.T Follicular Helper-Like Cells Are Involved in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica.Interleukin-6, S-Nitrosothiols, and Neurodegeneration in Different Central Nervous System Demyelinating Disorders: Is There a Relationship?
P2860
Q21146662-D1DD16EF-3070-49FE-9634-7C460710BD09Q26770664-F103C543-4117-46C4-8C83-FFB202344949Q26795577-B97A1CDC-0551-4776-8C5C-C7BB49BB3183Q26849719-23C1A58E-5A20-4BE6-88BE-B02054E669A7Q28077219-52B9334A-BC15-40FA-BBEC-53048665241BQ33562130-D9E86DD5-C072-4923-8AA1-EE2154486794Q34384966-0CFE48D9-A90D-4B62-BC86-D7DA4686A8D0Q35731510-88BB12AB-EC09-4D8D-8C7B-CF2611FBF6D5Q35897848-CE6D7663-B7D3-40C0-835C-D40180EF1AB6Q36359371-7F6453E4-42F6-4078-869A-09575A69A8CAQ36455070-EF66B141-6262-4082-9231-A21C00D622F4Q37520888-8FEBE91B-809C-429E-B05B-70EECA410FDDQ37645910-64828D37-8AA5-479C-BB63-E6C30F393EA7Q37699554-CEFE9412-CF3F-438B-A232-0576055480B7Q38617794-7D2BFC24-583E-4123-9D81-384B410A220EQ38798705-6A145CFE-51BD-4DA8-B53F-896B15679739Q38877460-945920BC-2CF8-49AF-BF15-AC65D56B1617Q38975695-C120C435-433F-4B76-89F7-9DC3CE8A63E2Q39150957-D41DCA43-E61A-4909-B576-DD5C5F6F3955Q39163678-E733A39F-41AF-405F-8088-D8AB7E6E262BQ40295389-37B40B1D-957B-4DB3-9F57-B623A42D5F79Q40425520-2932E30D-AF87-4A2C-969D-5B6B7F31AFBBQ40715894-0C21504F-D1E2-486F-A5BD-29740279136DQ41465773-B4418A93-57DE-4780-9767-80DFBB71E171Q46299475-7227423F-EBA3-44DA-A25E-65F48C292CE1Q48302225-CA1211C8-A47B-4CA1-90B6-8946E037CCF5Q55104293-6A29D86F-8D5C-4D56-9CA2-FF507F0288EDQ55107890-80BF40B1-55F7-48D7-922C-B55635B3A872Q55434832-8DC0B1A3-D32E-4D83-935A-680776C7766B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
B cells in MS and NMO: pathogenesis and therapy.
@en
type
label
B cells in MS and NMO: pathogenesis and therapy.
@en
prefLabel
B cells in MS and NMO: pathogenesis and therapy.
@en
P2860
P1476
B cells in MS and NMO: pathogenesis and therapy.
@en
P2093
Edgar Meinl
Markus Krumbholz
P2860
P2888
P304
P356
10.1007/S00281-014-0424-X
P577
2014-05-16T00:00:00Z
P5875
P6179
1025480823